Cargando…

Leukotriene Signaling as a Target in α-Synucleinopathies

Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are two common types of α-synucleinopathies and represent a high unmet medical need. Despite diverging clinical manifestations, both neurodegenerative diseases share several facets of their complex pathophysiology. Apart from α-synuclein a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strempfl, Katharina, Unger, Michael S., Flunkert, Stefanie, Trost, Andrea, Reitsamer, Herbert A., Hutter-Paier, Birgit, Aigner, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944962/ https://www.ncbi.nlm.nih.gov/pubmed/35327537 http://dx.doi.org/10.3390/biom12030346

Ejemplares similares

The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
por: Michael, Johanna, et al.
Publicado: (2021)

Cysteinyl leukotriene receptor 1 modulates autophagic activity in retinal pigment epithelial cells
por: Koller, Andreas, et al.
Publicado: (2020)

The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
por: Marschallinger, Julia, et al.
Publicado: (2020)

Chronobiological activity of cysteinyl leukotriene receptor 1 during basal and induced autophagy in the ARPE-19 retinal pigment epithelial cell line
por: Koller, Andreas, et al.
Publicado: (2021)

Decreased Plasma Aβ in Hyperlipidemic APP(SL) Transgenic Mice Is Associated with BBB Dysfunction
por: Löffler, Tina, et al.
Publicado: (2016)

Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value
por: Loeffler, Tina, et al.
Publicado: (2020)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
por: Flunkert, Stefanie, et al.
Publicado: (2022)

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
por: Aigner, Ludwig, et al.
Publicado: (2020)

Hepatic and neuronal phenotype of NPC1(−/−) mice
por: Santiago-Mujica, Estibaliz, et al.
Publicado: (2019)

Constant Levels of Tau Phosphorylation in the Brain of htau Mice
por: Neddens, Joerg, et al.
Publicado: (2020)

Evaluation of Neuropathological Features in the SOD1-G93A Low Copy Number Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
por: Molnar-Kasza, Agnes, et al.
Publicado: (2021)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Non-Selective Calcium Channel Blocker Bepridil Decreases Secondary Pathology in Mice after Photothrombotic Cortical Lesion
por: Lipsanen, Anu, et al.
Publicado: (2013)

Metabolic, Phenotypic, and Neuropathological Characterization of the Tg4-42 Mouse Model for Alzheimer’s Disease
por: Hinteregger, Barbara, et al.
Publicado: (2021)

Leukotriene signaling as molecular correlate for cognitive heterogeneity in aging: an exploratory study
por: Mrowetz, Heike, et al.
Publicado: (2023)

Stable Mutated tau441 Transfected SH-SY5Y Cells as Screening Tool for Alzheimer’s Disease Drug Candidates
por: Löffler, Tina, et al.
Publicado: (2012)

Neuroinflammation and related neuropathologies in APP(SL) mice: further value of this in vivo model of Alzheimer’s disease
por: Löffler, Tina, et al.
Publicado: (2014)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model
por: Etxeberria-Rekalde, Estibaliz, et al.
Publicado: (2021)

Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies
por: Trošt, Maja, et al.
Publicado: (2019)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Transgene integration causes RARB downregulation in homozygous Tg4–42 mice
por: Hinteregger, Barbara, et al.
Publicado: (2020)

Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models
por: Sharghi, Shirin, et al.
Publicado: (2023)

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
por: Shin, Junghwan, et al.
Publicado: (2020)

Autonomic Dysfunction in α-Synucleinopathies
por: Mendoza-Velásquez, José Javier, et al.
Publicado: (2019)

Selective vulnerability in α-synucleinopathies
por: Alegre-Abarrategui, Javier, et al.
Publicado: (2019)

Phosphorylation of different tau sites during progression of Alzheimer’s disease
por: Neddens, Joerg, et al.
Publicado: (2018)

Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
por: Filip, Thomas, et al.
Publicado: (2021)

Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
por: Michael, J., et al.
Publicado: (2020)

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
por: Rabl, R., et al.
Publicado: (2017)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms
por: Scherz, Barbara, et al.
Publicado: (2018)

Immunotherapies in Huntington's disease and α-Synucleinopathies
por: Fatoba, Oluwaseun, et al.
Publicado: (2020)

Neurons and Glia Interplay in α-Synucleinopathies
por: Mavroeidi, Panagiota, et al.
Publicado: (2021)

Autophagy in α-Synucleinopathies—An Overstrained System
por: Fellner, Lisa, et al.
Publicado: (2021)

The Interplay between α-Synuclein and Microglia in α-Synucleinopathies
por: Deyell, Jacob S., et al.
Publicado: (2023)

Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
por: Schiffer, Victoria, et al.
Publicado: (2020)

Dysregulation of astrocytic Ca(2+) signaling and gliotransmitter release in mouse models of α-synucleinopathies
por: Nanclares, Carmen, et al.
Publicado: (2023)

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
por: Fouka, Maria, et al.
Publicado: (2020)

α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
por: Abdelkarim, Hazem, et al.
Publicado: (2018)

Disease modifying effect of adiponectin in model of α-synucleinopathies
por: Sekiyama, Kazunari, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kc7qm9c20e5gepj46ur0qe5158